QUOTE AND NEWS
SeekingAlpha  7 hrs ago  Comment 
By Spencer Osborne: While there have been rumblings in the past about the advertising campaign with Arena Pharmaceuticals' (NASDAQ:ARNA) anti-obesity drug Belviq, the most recent two weeks have demonstrated a distinct shift in the television...
SeekingAlpha  Sep 21  Comment 
By Spencer Osborne: Arena Pharmaceuticals' (NASDAQ:ARNA) anti-obesity pill Belviq saw a full recovery from a holiday dip in sales last week with a 15% gain this week. Sales in the most recent week demonstrated a full recovery plus a modest...
SeekingAlpha  Sep 19  Comment 
By Spencer Osborne: Arena Pharmaceuticals (NASDAQ:ARNA) seems to always have something compelling happening. Last week I published an article that assessed the impact of Belviq and phentermine from the perspective of the study design by a doctor...
Motley Fool  Sep 17  Comment 
Highlights from Arena Pharmaceuticals' conference call with investors.
SeekingAlpha  Sep 17  Comment 
By Spencer Osborne: Like pretty much anyone invested in Arena Pharmaceuticals (NASDAQ:ARNA), I saw the snapshot of a poster relating to the study of a doctor which scripted Belviq and phentermine to patients. I also saw the subject written about....
TheStreet.com  Sep 16  Comment 
BOSTON (TheStreet) -- The Areniacs -- my term of endearmentafor the retail-investor supporters of Arena Pharmaceuticals a-- have been burning up the Internet message boards for the past few days with talk of weight-loss results from a...
SeekingAlpha  Sep 12  Comment 
By Spencer Osborne: Sales of Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) saw an anticipated dip this week due to the Labor Day holiday. Sales were down 12% from last week's numbers according to industry source IMS Health. While seeing sales...
SeekingAlpha  Sep 12  Comment 
By Alexander Maxwell: Orexigen Therapeutics (NASDAQ:OREX) investors were finally rewarded for their patience, after obtaining FDA approval for Orexigen's weight-loss drug Contrave. Contrave will face stiff competition in the market from both Arena...
SeekingAlpha  Sep 12  Comment 
By Spencer Osborne: The anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) is finally seeing the type of action in the advertising space that investors can quantify as a compelling shift. The shift began on September 8th and aligned...
Motley Fool  Sep 12  Comment 
A new weight loss pill from Orexigen will face stiff competition from Arena's Belviq and may soon have to compete against Novo Nordisk's Saxenda.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki